Terns Pharmaceuticals Showcases TERN-701 as Potential Best-in-Disease Therapy for CML in New Corporate Presentation

Reuters01-12

Terns Pharmaceuticals Showcases TERN-701 as Potential Best-in-Disease Therapy for CML in New Corporate Presentation

Terns Pharmaceuticals Inc. $(TERN)$ highlighted recent progress on its lead candidate TERN-701, an oral allosteric BCR-ABL inhibitor for the treatment of chronic myeloid leukemia (CML), in its latest corporate presentation. TERN-701 demonstrated a major molecular response (MMR) rate of 75% at 24 weeks in a Phase 1 study among patients with chronic phase CML at doses of 320 mg or higher. The candidate showed a favorable safety and tolerability profile, with no dose limiting toxicities or maximum tolerated dose identified and the majority of treatment emergent adverse events reported as low grade. As of December 2025, the study had enrolled more than 85 participants, including a significant proportion with prior exposure to other CML therapies. Terns reported approximately $1.0 billion in cash and cash equivalents, with a financial runway projected into 2031. Multiple clinical and regulatory milestones for TERN-701 are anticipated in 2026 and beyond. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602551045?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 21:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602551045","market":"nz","top_or_hot":-1,"title":"Terns Pharmaceuticals Showcases TERN-701 as Potential Best-in-Disease Therapy for CML in New Corporate Presentation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Terns Pharmaceuticals Showcases TERN-701 as Potential Best-in-Disease Therapy for CML in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Terns Pharmaceuticals Inc. <a href=\"https://laohu8.com/S/TERN\">$(TERN)$</a> highlighted recent progress on its lead candidate TERN-701, an oral allosteric BCR-ABL inhibitor for the treatment of chronic myeloid leukemia (CML), in its latest corporate presentation. TERN-701 demonstrated a major molecular response (MMR) rate of 75% at 24 weeks in a Phase 1 study among patients with chronic phase CML at doses of 320 mg or higher. The candidate showed a favorable safety and tolerability profile, with no dose limiting toxicities or maximum tolerated dose identified and the majority of treatment emergent adverse events reported as low grade. As of December 2025, the study had enrolled more than 85 participants, including a significant proportion with prior exposure to other CML therapies. Terns reported approximately $1.0 billion in cash and cash equivalents, with a financial runway projected into 2031. Multiple clinical and regulatory milestones for TERN-701 are anticipated in 2026 and beyond. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Terns Pharmaceuticals Showcases TERN-701 as Potential Best-in-Disease Therapy for CML in New Corporate Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTerns Pharmaceuticals Showcases TERN-701 as Potential Best-in-Disease Therapy for CML in New Corporate Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-12 21:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Terns Pharmaceuticals Showcases TERN-701 as Potential Best-in-Disease Therapy for CML in New Corporate Presentation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Terns Pharmaceuticals Inc. <a href=\"https://laohu8.com/S/TERN\">$(TERN)$</a> highlighted recent progress on its lead candidate TERN-701, an oral allosteric BCR-ABL inhibitor for the treatment of chronic myeloid leukemia (CML), in its latest corporate presentation. TERN-701 demonstrated a major molecular response (MMR) rate of 75% at 24 weeks in a Phase 1 study among patients with chronic phase CML at doses of 320 mg or higher. The candidate showed a favorable safety and tolerability profile, with no dose limiting toxicities or maximum tolerated dose identified and the majority of treatment emergent adverse events reported as low grade. As of December 2025, the study had enrolled more than 85 participants, including a significant proportion with prior exposure to other CML therapies. Terns reported approximately $1.0 billion in cash and cash equivalents, with a financial runway projected into 2031. Multiple clinical and regulatory milestones for TERN-701 are anticipated in 2026 and beyond. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL4Tc7PR:1","article_id":"2602551045","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602551045","pubTimestamp":1768223606,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Terns Pharmaceuticals Inc.  highlighted recent progress on its lead candidate TERN-701, an oral allosteric BCR-ABL inhibitor for the treatment of chronic myeloid leukemia , in its latest corporate presentation. TERN-701 demonstrated a major molecular response  rate of 75% at 24 weeks in a Phase 1 study among patients with chronic phase CML at doses of 320 mg or higher. The candidate showed a favorable safety and tolerability profile, with no dose limiting toxicities or maximum tolerated dose identified and the majority of treatment emergent adverse events reported as low grade. As of December 2025, the study had enrolled more than 85 participants, including a significant proportion with prior exposure to other CML therapies. Terns reported approximately $1.0 billion in cash and cash equivalents, with a financial runway projected into 2031. Multiple clinical and regulatory milestones for TERN-701 are anticipated in 2026 and beyond. You can access the full presentation through the link b","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","TERN":"Terns Pharmaceuticals, Inc."},"translate_title":"Terns Pharmaceuticals在新的公司演示中展示了TERN-701作为CML潜在的最佳疾病疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TERN":0.9},"content_text":"Terns Pharmaceuticals Showcases TERN-701 as Potential Best-in-Disease Therapy for CML in New Corporate Presentation\n    \n\n        Terns Pharmaceuticals Inc. $(TERN)$ highlighted recent progress on its lead candidate TERN-701, an oral allosteric BCR-ABL inhibitor for the treatment of chronic myeloid leukemia (CML), in its latest corporate presentation. TERN-701 demonstrated a major molecular response (MMR) rate of 75% at 24 weeks in a Phase 1 study among patients with chronic phase CML at doses of 320 mg or higher. The candidate showed a favorable safety and tolerability profile, with no dose limiting toxicities or maximum tolerated dose identified and the majority of treatment emergent adverse events reported as low grade. As of December 2025, the study had enrolled more than 85 participants, including a significant proportion with prior exposure to other CML therapies. Terns reported approximately $1.0 billion in cash and cash equivalents, with a financial runway projected into 2031. Multiple clinical and regulatory milestones for TERN-701 are anticipated in 2026 and beyond. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Terns Pharmaceuticals Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602551045","isCrawlerRequest":true}